To the central content area :::
:::Listed Companies > Listed Companies Info. > Main Board Companies > Listed Company Profile

General Stock Board Listed Company Profile

6785 Alar
Company Profile
Chairman CEO Spokesperson Tel Address Date of Listing (Regular)
Charles Lin Yung-Shun Wen Yung-Shun Wen 04-24637115 5F., No.32, Keya Rd., Daya Dist.Taichung City, Taiwan (R.O.C.) 2024/01/24
Industry Main Business
Biotechnology and Medical Care We focus on developing long-acting release drug products for CNS disorders and chronic diseases, which mainly include opioid use disorder, chronic pain, and major depressive disorder. These chronic diseases not only cause long-term burdens to the patients and their families but also consume huge social costs. Long-acting release product is a solution to improve medical quality, enhance patient’s compliance, and increase drug adherence. The unique long-acting release platform developed by Alar is different from the current long-acting technologies. Drug products developed by our platform have distinctive characteristics such as low viscosity, small injection volume, and smooth drug release profile with fewer side effects, which provide a better medical choice for patients. We believe that with the corporate philosophy of improving medical quality, it will reach the milestones of excellence in developing long-acting drug products.
Market Information ( 2024/05/29 )
Shr. Vol. Highest Lowest Closed Change Transaction TurnOver(%) long
563.58 293.00  285.00  291.00  3.50  1816 .00 N/A N/A
Trading method Fun
price or
on T day
Announcement of Irregularity
TPEx measures
With warrants Can be shorted or margined? Detail
Normal N N N Y N Today History
Financial Reports
Cash Flows Items
(NT$ thousand)
Cash flows from operating activities
Cash flows from investing activities
Cash flows from financing activities
Current assets
Non-current assets
Total assets
Current liabilities
Non-current liabilities
Total liabilities
Share capital
Capital surplus
Retained earnings
Other equity interest
Treasury shares
Total equity attributable to owners of parent
Non-controlling interests
Total equity
Book Value per share(NT$)
Comprehensive Income Operating revenue
Operating costs
Gross profit from operations
Operating expenses
Net other income (expenses)
Net operating income
Non-operating income and expenses
Profit before tax
Tax expense
Profit from continuing operations
Profit from discontinued operations
Other comprehensive income
Comprehensive income
Basic earnings per share
 Auditor's report on latest financial statements: auditor's report:
 More detail:MOPS
 Foreign issuers’ information is disclosed in consolidated statements.